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Abstract Hypertension in the term or preterm neonate
may be seen in up to 2% of all infants cared for in the
modern neonatal intensive care unit. Although the defini-
tion of hypertension in this age group has not been com-
pletely standardized, recent studies have provided new
normative data that may be used to facilitate identifica-
tion of such infants. Common causes of hypertension in
neonates include thromboembolic events related to um-
bilical catheterization, congenital problems such as aor-
tic coarctation, structural renal malformations and reno-
vascular disease, as well as acquired renal disease and
certain medications. A careful history and physical ex-
amination will usually identify the probable cause in
most cases without the need for extensive laboratory or
radiologic testing. Therapy of neonatal hypertension
should be tailored to the severity of the blood pressure
elevation, and to the underlying cause of hypertension as
appropriate. A wide range of therapeutic agents are now
available for management of neonatal hypertension in
both the acute and chronic settings. In most cases hyper-
tension will resolve, but some infants may require pro-
longed treatment.
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Introduction
Hypertension as a clinical problem in newborn infants
was first recognized in the 1970s [1]. However, recent
advances in our ability to identify, evaluate and care for
hypertensive infants, coupled with advances in the prac-
tice of neonatology in general, have lead to an increased
awareness of hypertension in modern neonatal intensive
care units (NICUs). Since most hypertension in infants is
related to renovascular or renal parenchymal disease [2,
3], the evaluation and management of neonatal hyperten-
sion frequently requires the expertise of a pediatric neph-
rologist. This review will focus on the differential diag-
nosis of hypertension in the neonate, the optimal diag-
nostic evaluation, and both acute and chronic antihyper-
tensive therapy.
Definition and incidence of neonatal hypertension
Defining what is considered a normal blood pressure in
newborn infants is a complex task. Just as blood pressure
in older children has been demonstrated to increase with
increasing age and body size [4], studies in both term
and preterm infants have demonstrated that blood pres-
sure in neonates increases with both gestational and
postconceptual age, as well as with birth weight [5–11].
Extremely useful data in this regard has recently been
published by Zubrow et al. [9], who prospectively ob-
tained serial blood pressure measurements from 695 in-
fants admitted to several NICUs in a large metropolitan
area over a period of 3 months. From these data, they
were able to define the mean plus upper and lower 95%
confidence limits for blood pressure for the infants stud-
ied; their data clearly demonstrated increases in blood
pressure with increasing gestational age, birth weight
and postconceptual age (Figs. 1–3). Based on these data,
we would consider an infant’s blood pressure to be ele-
vated if it fell above the upper limit of the 95% confi-
dence interval for infants of similar gestational or post-
conceptual age and size.
For older infants found to be hypertensive following
discharge from the NICU [12], the percentile curves gen-
erated by the Second Task Force (Fig. 4) [13] appear to
be the most useful. Based on serial blood pressure mea-
surements obtained from nearly 13,000 infants, these
curves allow blood pressure to be characterized as nor-
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mal or elevated not only by age and gender, but also by
size, albeit to a somewhat limited extent. Hypertension
in this age group would be defined as blood pressure ele-
vation above the 95th percentile for infants of similar
age, size and gender.
Although the upper limit of normal blood pressure
has been defined as the 95th percentile, the actual inci-
dence of hypertension in neonates is quite low, ranging
from 0.2% to 3% in most reports [1, 2, 14–16]. It is so
unusual in otherwise healthy term infants that routine
blood pressure determination is not advocated for this
group [17]. For premature and otherwise high-risk new-
borns admitted to modern NICUs, however, the picture
can be quite different. In a review of over 3,000 infants
admitted to a Chicago NICU, the overall incidence of
hypertension was found to be 0.81% [16]. Hypertension
was considerably more common in infants with broncho-
pulmonary dysplasia, patent ductus arteriosus, intraven-
tricular hemorrhage or that had indwelling umbilical ar-
terial catheters. In this latter group, approximately 9% of
the infants studied developed hypertension.
Hypertension may also be detected well after dis-
charge from the NICU. In a retrospective review of over
650 infants seen in follow-up after discharge from a
teaching hospital NICU, Friedman and Hustead [12]
found an incidence of hypertension (defined as a systolic
blood pressure of greater than 113 mmHg on three con-
secutive visits over 6 weeks) of 2.6%. Hypertension in
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Fig. 1 Linear regression of mean systolic and diastolic blood
pressures by birth weight on day 1 of life, with 95% confidence
limits (upper and lower dashed lines). Reproduced from Zubrow
et al. [9], with permission from the copyright holders, Stockton




















































Fig. 2 Linear regression of mean systolic and diastolic blood
pressures by gestational age on day 1 of life, with 95% confidence
limits (upper and lower dashed lines). Reproduced from Zubrow
et al. [9], with permission from the copyright holders, Stockton
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Fig. 3 Linear regression of mean systolic and diastolic blood
pressures by postconceptual age in weeks, with 95% confidence
limits (upper and lower dashed lines). Reproduced from Zubrow
et al. [9], with permission from the copyright holders, Stockton
Press, a division of Nature America
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2 months post-term when corrected for prematurity. Al-
though the differences were not significant, infants in
this study who developed hypertension tended to have
lower initial Apgar scores and slightly longer NICU
stays than infants who remained normotensive, indicat-
ing a somewhat greater likelihood of developing hyper-
tension in sicker babies, a finding similar to that of Singh
et al. [16]. Even with the increasing rates of survival of
premature infants, however, hypertension remains a rela-
tively infrequent clinical problem that is primarily con-
fined to the NICU.
Causes of hypertension in neonates
As in older infants and children, the causes of hyperten-
sion in neonates are numerous (Table 1), with the two
largest categories being renovascular and other renal pa-
renchymal diseases [1–3, 12, 14–16]. More specifically,
umbilical artery catheter-associated thromboembolism
affecting either the aorta and/or the renal arteries proba-
bly accounts for the majority of cases of hypertension
seen in the typical NICU. A clear association between
use of umbilical arterial catheters and development of ar-
terial thrombi was first demonstrated in the early 1970s
by Neal et al. [18]. They performed aortography at the
time of umbilical artery removal in a group of 19 infants,
demonstrating thrombus formation in 18 of the 19 in-
fants, as well as several instances of clot fragmentation
and embolization. Thrombosis was also seen at autopsy
in 7 of 12 infants who had died, for an overall incidence
of 25 out of 31 infants, or approximately 81% of infants
studied.
Following the report of Neal et al., the association be-
tween umbilical arterial catheter-associated thrombi and
the development of neonatal hypertension was confirmed
by several other investigators [19–24]. Hypertension was
demonstrated in infants who had undergone umbilical ar-
terial catheterization even when thrombi could not be
demonstrated in the renal arteries. Rates of thrombus for-
mation have generally been much lower than in the re-
port of Neal et al., typically in the range of 25% [19, 25,
26]. Although there have been several studies that have
examined duration of line placement and line position
(“low” vs “high”) as factors involved in thrombus forma-
tion, these data have not been conclusive [25–27]. Thus,
the assumption has been made that the cause of hyper-
tension in such cases is related to thrombus formation at
the time of line placement, probably related to disruption
of the vascular endothelium of the umbilical artery. Such
thrombi may then embolize to the kidneys, causing areas
of infarction and increased renin release. A similar phe-
nomenon has been reported in infants with dilatation of
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Fig. 4 Age-specific percentiles for blood pressure in boys (a) and
girls (b) from birth to 12 months of age. Reproduced with permis-
sion from [13]
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nant and autosomal recessive polycystic kidney disease
(PKD) may present in the newborn period with severe
nephromegaly and hypertension [35, 36]. With recessive
PKD for example, the majority of affected infants will be
discovered to be hypertensive during the 1st year of life
[35]. The most severely affected infants with PKD are at
risk for development of congestive heart failure due to
severe, malignant hypertension. Although much less
common than in PKD, hypertension has also been re-
ported in infants with unilateral multicystic dysplastic
kidneys [14, 37–39]. This is somewhat paradoxical, as
such kidneys are usually thought to be non-functional.
Renal obstruction may be accompanied by hyperten-
sion, even in the absence of renal arterial compression.
This has been seen for example in infants with congeni-
tal ureteropelvic-junction obstruction [12, 14, 16], and
sometimes may persist following surgical correction of
the obstruction [40]. Ureteral obstruction by other intra-
abdominal masses may also be accompanied by hyper-
tension. The mechanism of hypertension in such instanc-
es is unclear, although the renin-angiotensin system has
been implicated [41, 42]. Finally, unilateral renal hypo-
plasia may also present with hypertension [43], although
this is uncommon.
Hypertension due to acquired renal parenchymal dis-
ease is less common than that due to congenital renal ab-
normalities. However, severe acute tubular necrosis, in-
terstitial nephritis or cortical necrosis may be accompa-
nied by significant hypertension [14, 16], usually on the
basis of volume overload or hyperreninemia. Hemolytic
uremic syndrome, which has been described in both term
and preterm infants, is usually also accompanied by hy-
pertension. Such hypertension may be quite difficult to
control, requiring multiple agents [44].
Hypertension as a consequence of bronchopulmonary
dysplasia (BPD) was first described in the mid-1980s by
Abman et al. [45]. In a study of 65 infants discharged
from an NICU, the instance of hypertension in infants
with BPD was 43%, versus an incidence of 4.5% in in-
fants without BPD. Investigators were unable to identify
a clear cause of hypertension, but postulated that hypox-
emia might be involved. Over half of the infants with
BPD who developed hypertension did not manifest it un-
til discharged from the NICU, highlighting the need for
measurement of blood pressure in NICU “graduates,”
whether or not they have lung disease [12].
The findings of Abman et al. have been reproduced by
other investigators, most recently in 1998 by Alagappan
and Malloy [46], who found that hypertension was twice as
common in very low birth weight infants with BPD com-
pared to the incidence in all very low birth weight infants.
Development of hypertension appeared to be correlated
with the severity of pulmonary disease, as all of the hyper-
tensive infants required supplemental oxygen and ami-
nophylline. A greater need for diuretics and bronchodila-
tors has also been shown to correlate with the development
of hypertension in infants with severe BPD [47]. These ob-
servations reinforce the impression that infants with severe
BPD are clearly at increased risk and need close monitor-
Table 1 Causes of neonatal hypertension (ECMO extracorporeal
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Other renovascular problems may also lead to neona-
tal hypertension. Renal venous thrombosis classically
presents with the triad of hypertension, gross hematuria,
and an abdominal mass. Hypertension may be quite se-
vere in such cases and may persist beyond the neonatal
period [13, 29, 30]. Fibromuscular dysplasia leading to
renal arterial stenosis is another important cause of reno-
vascular hypertension in the neonate. Many of these in-
fants may have main renal arteries that appear fairly nor-
mal on angiography but demonstrate significant branch
vessel disease that can cause severe hypertension [31]. In
addition, renal arterial stenosis may also be accompanied
by mid-aortic coarctation and cerebral vascular stenoses
[31]. Other vascular abnormalities may also lead to hy-
pertension in the neonate, including idiopathic arterial
calcification [32, 33] and renal artery stenosis secondary
to congenital rubella infection [34]. Finally, mechanical
compression of one or both renal arteries by tumors, hy-
dronephrotic kidneys, or other abdominal masses may
also lead to hypertension.
The next largest group of infants with hypertension
are neonates who have congenital renal parenchymal ab-
normalities. It is well known that both autosomal domi-
have all been proposed as causative factors [61, 62].
Given the widespread use of ECMO both in neonates
and in older children, this problem is ripe for further in-
vestigation.
Clinical presentation and diagnostic approach
In many infants, hypertension will be discovered on rou-
tine monitoring of vital signs, particularly in the most
acutely ill infants. However, other classic presentations
of neonatal hypertension have been described. Conges-
tive heart failure and cardiogenic shock represent life-
threatening consequences of hypertension that may re-
solve with appropriate blood pressure reduction [63]. In
the less acutely ill infant, feeding difficulties, unex-
plained tachypnea, apnea, lethargy, irritability, or sei-
zures may constitute symptoms of unsuspected hyperten-
sion. In older infants who have been discharged from the
nursery, unexplained irritability or failure to thrive may
be the only manifestations of hypertension.
No matter what the presentation, it is crucial that
blood pressure is being measured accurately so that hy-
pertension will be correctly identified. Fortunately, in
most acutely ill neonates, blood pressure is usually mon-
itored directly via an indwelling arterial catheter either in
the radial or umbilical artery. This method provides the
most accurate blood pressure readings, and is clearly
preferable to other methods [64]. In addition to accurate-
ly measuring blood pressures, such catheters are also
crucial in careful management of hypertension, particu-
larly in infants with extremely severe blood pressure ele-
vation.
Automated, oscillometric devices are the most com-
mon alternative method of blood pressure measurement
in most NICUs. Although readings obtained using such
devices may differ slightly from intra-arterial blood pres-
sure measurements [65], they are easy to use and provide
the ability to follow blood pressure trends over time.
They are especially useful for infants who require blood
pressure monitoring after discharge from the NICU [66].
When using such devices, however, attention should be
paid to using a properly sized cuff, and also to the ex-
tremity used. Most normative blood pressure data, not
only in infants but also in older children, have been col-
lected using blood pressures obtained in the right arm
[13]. Since blood pressures obtained in the leg may be
higher than those obtained in the arm [67, 68], the use of
other extremities for routine blood pressure determina-
tion may complicate to some extent the evaluation of hy-
pertension. Nursing staff should document the extremity
used for blood pressure determinations and try to use the
same extremity for subsequent determinations if possi-
ble. Finally, the infant’s state of activity may also affect
the accuracy of blood pressure readings. Increased activ-
ity, including oral feeding, increases blood pressure [5,
69]. It may, therefore, be important to obtain blood pres-
sure readings while infants are sleeping to obtain the
most accurate readings.
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ing for the development of hypertension. This is especially
true in infants who require ongoing treatment with theoph-
ylline preparations and/or corticosteroids.
Hypertension may also be seen in disorders of several
other organ systems. Coarctation of the thoracic aorta is
easily detected in the newborn period, and has been re-
ported in numerous case series of neonatal hypertension
[2, 3, 12, 14, 16]. Hypertension may persist in these in-
fants even after surgical repair of the coarctation. Repair
early in infancy seems to lead to an improved long-term
outcome compared to delayed repair [48]. Endocrinolog-
ic disorders, particularly congenital adrenal hyperplasia
[49, 50], hyperaldosteronism [51] and hyperthyroidism
[52] constitute easily recognizable clinical entities that
are accompanied by hypertension.
Iatrogenic causes of hypertension constitute another
important category of diagnoses. Medications given to
infants for treatment of pulmonary disease such as dexa-
methasone and aminophylline have clearly been shown
to elevate blood pressure [53, 54]. In addition, high dos-
es of adrenergic agents, prolonged use of pancuronium,
or administration of phenylephrine ophthalmic drops
[55] may raise blood pressure. Such hypertension typi-
cally resolves when the offending agent is discontinued
or its dose reduced. For infants receiving prolonged par-
enteral nutrition (TPN), hypertension may result from
salt and water overload, or from hypercalcemia caused
either directly by excessive calcium intake, or indirectly
by vitamin A or D intoxication.
Substances ingested during pregnancy may also lead
to significant problems with hypertension in the neonate.
In particular, maternal cocaine use may have a number
of undesirable effects on the developing kidney that may
lead to hypertension [56]. Hypertension has also been re-
ported to occur in infants of drug-addicted mothers with-
drawing from heroin.
Tumors, including neuroblastoma, Wilms tumor, and
mesoblastic nephroma may all present in the neonatal
period and may produce hypertension, either because of
compression of the renal vessels or ureters, or because of
production of vasoactive substances such as catechola-
mines [12, 57–60]. Neurologic problems such as sei-
zures, intracranial hypertension and pain constitute fairly
common causes of episodic hypertension. In the modern
NICU, postoperative pain must not be overlooked as a
cause of hypertension. Provision of adequate analgesia
may constitute the only required “antihypertensive” in
such infants.
There are numerous other miscellaneous causes of
hypertension in neonates, the most common of which
are listed in Table 1. Of these, hypertension associated
with extracorporeal membrane oxygenation (ECMO)
deserves comment. This may be seen in up to 50% of
infants requiring ECMO [61], and may result in serious
complications, including intracranial hemorrhage [62].
Despite extensive investigation, the exact pathogenesis
of this form of hypertension remains poorly under-
stood. Fluid overload, altered handling of sodium and
water, and derangements in atrial baroceptor function
ly, plasma renin may be falsely elevated by medications
that are commonly used in the NICU, such as aminoph-
ylline [72]. Despite these difficulties, assessment of plas-
ma renin activity may be helpful in the evaluation of
some infants, especially when elevated, and is therefore
usually included as part of the initial laboratory evalua-
tion.
Ultrasound imaging of the genitourinary tract is a rel-
atively inexpensive, noninvasive, and quick study that
should be obtained in all hypertensive infants. An accu-
rate renal ultrasound can help uncover potentially cor-
rectable causes of hypertension such as renal venous
thrombosis [29], may detect aortic and/or renal arterial
thrombi [19, 24], and can identify anatomic renal abnor-
malities or other congenital renal diseases. For these rea-
sons, ultrasound has largely replaced intravenous pyel-
ography, which has little if any use in the routine assess-
ment of neonatal hypertension.
For infants with extremely severe blood pressure ele-
vation, angiography may be necessary. In our experi-
ence, a formal angiogram utilizing the traditional femo-
ral venous approach offers the most accurate method of
diagnosing renal arterial stenosis, particularly given the
high incidence of intrarenal branch vessel disease in
children with fibromuscular dysplasia [31]. In extremely
small infants, it may be appropriate to defer angiography,
managing the hypertension medically until the baby is
large enough for an angiogram to be performed safely.
Although nuclear scanning has been shown in some
studies to demonstrate abnormalities of renal perfusion
caused by thromboembolic phenomenon [1, 15, 16, 23,
28], in our practice it has had little role in the assessment
of infants with hypertension, primarily due to the diffi-
culties in obtaining accurate, interpretable results in this
age group. Other studies, including echocardiograms and
voiding cystourethrograms, should be obtained as indi-
cated.
Therapy of neonatal hypertension
Today’s clinician has available an ever-expanding list of
agents that can be used for treatment of neonatal hyper-
tension (Tables 3, 4). Prior to embarking on drug thera-
py, however, the infant’s clinical status should be as-
sessed and any easily correctable iatrogenic causes of
hypertension addressed, such as infusions of inotropic
agents, volume overload, or pain. Following this, an an-
tihypertensive agent should be chosen that is most ap-
propriate for the specific clinical situation. For the ma-
jority of acutely ill infants, particularly those with severe
hypertension, it has been our experience that continuous
intravenous infusions are the most appropriate approach.
While intermittently administered agents also have a role
in the management of hypertension, the wide fluctua-
tions in blood pressure frequently seen when these
agents are utilized make them inappropriate for treat-
ment of severe hypertension. The advantage of intrave-
nous infusions are numerous, most importantly including
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Diagnosing the etiology of hypertension is a fairly
straightforward task in most hypertensive neonates. A
relatively focused history should be obtained, paying at-
tention to determining whether there were any pertinent
prenatal exposures, as well as to the particulars of the in-
fant’s nursery course and any concurrent conditions. The
procedures that the infant has undergone (e.g., umbilical
catheter placement) should be reviewed, and their cur-
rent medication list should be scrutinized.
The physical examination, likewise, should be fo-
cused on obtaining pertinent information to assist in nar-
rowing the differential diagnosis. Blood pressure read-
ings should be obtained in all four extremities to rule out
coarctation of the thoracic aorta. The general appearance
of the infant should be assessed, with particular attention
paid to the presence of dysmorphic features that may in-
dicate an obvious diagnosis such as congenital adrenal
hyperplasia. Careful cardiac and abdominal examination
should be performed. The presence of a flank mass or of
an epigastric bruit may point the clinician towards diag-
nosis of either ureteropelvic junction obstruction or renal
arterial stenosis, respectively.
In most instances, few laboratory data are needed in
the evaluation of neonatal hypertension, as the correct
diagnosis is usually suggested by the history and physi-
cal examination. It is important to assess renal function,
as well as to examine a specimen of the urine to ascer-
tain the presence of renal parenchymal disease. Chest 
x-ray may be useful as an adjunctive test in infants with
congestive heart failure, or in those with a murmur on
physical examination. Other diagnostic studies, such as
cortisol, aldosterone, or thyroxine levels, should be ob-
tained when there is pertinent history (Table 2).
Determination of plasma renin activity is frequently
performed in the assessment of neonates with hyperten-
sion [14], although there are few data on what consti-
tutes normal values for infants, particularly for prema-
ture infants. The data that are available indicate that re-
nin values are typically quite high in infancy, at least in
term newborns [70, 71]. Although renal arterial stenosis
and thromboembolic phenomenon are typically consid-
ered high renin forms of hypertension, a peripheral renin
level may not be elevated in such infants despite the
presence of significant underlying pathology. Converse-
Table 2 Diagnostic testing in neonatal hypertension (CBC com-
plete blood count, VMA/HVA vanillylmandelic acid/homovanillic
acid, VCUG voiding cystourethrograms)
Generally useful Useful in selected infants
Urinalysis (± culture) Thyroid studies




Plasma renin Abdominal/pelvic ultrasound
Chest X-ray VCUG




the ability quickly to increase or decrease the rate of in-
fusion to achieve the desired level of blood pressure con-
trol. As in patients of any age with malignant hyperten-
sion, care should be taken to avoid too rapid a reduction
in blood pressure [73, 74] to avoid cerebral ischemia and
hemorrhage, a problem that premature infants in particu-
lar are already at increased risk for due to the immaturity
of their periventricular circulation. Here again, continu-
ous infusions of intravenous antihypertensives offer a
distinct advantage.
Unfortunately, there are few data available regarding
the use of these agents in neonates, so in many cases the
choice of agent will depend on the individual clinician’s
experience. Our experience [75] and that of others [76]
suggests that infusions of the calcium channel blocker
nicardipine may be particularly useful in this population.
Other drugs that have been successfully used in neonates
include esmolol [77], labetalol and nitroprusside [73].
Whatever agent is used, blood pressure should be moni-
tored continuously via an indwelling arterial catheter, or
else by frequently repeated (Q 10–15 min.) cuff readings
so that the dose can be titrated to achieve the desired de-
gree of blood pressure control.
For some infants, intermittently administered intrave-
nous agents do have a role in therapy. Hydralazine and
labetalol in particular may be useful in infants with mild-
to-moderate hypertension that are not yet candidates for
oral therapy because of gastrointestinal dysfunction.
Enalaprilat, the intravenous angiotensin converting en-
zyme inhibitor, has also been reported to be useful in the
treatment of neonatal renovascular hypertension [78, 79].
However, in our experience, this agent should be used
with great caution. Even doses at the lower end of pub-
lished ranges may lead to significant, prolonged hypo-
tension and oliguric acute renal failure.
Oral antihypertensive agents (Table 4) are best re-
served for infants with less severe hypertension or in-
fants whose acute hypertension has been controlled with
intravenous infusions and are ready to be transitioned to
chronic therapy. Captopril in particular is a useful agent
for many causes of neonatal hypertension and is our oral
drug of choice for most infants seen in our unit. Care
must be taken to avoid giving a dose that is too high to
premature infants, as they may have an exaggerated fall
in blood pressure following captopril administration
[80]. For infants whose blood pressure is unable to be
controlled by captopril alone, the addition of a diuretic
frequently will result in the desired degree of blood pres-
sure control. Beta blockers may need to be avoided in
chronic therapy of neonatal hypertension, particularly in
infants with chronic lung disease. In such infants, diuret-
ics may have a beneficial effect not only in controlling
blood pressure but also in improving pulmonary function
[81]. Other drugs that we have found useful in some in-
fants include hydralazine, minoxidil and the calcium
channel blocker isradipine [82]. When a vasodilator is
indicated, isradipine may be superior to the older agents
hydralazine and minoxidil since it can be compounded
into a stable suspension [83] that can be dosed with ac-
curacy, even in tiny infants. We no longer use nifedipine
in our unit because of the difficulty in administering
small doses, and because of the rapid, profound, and
short-lived drops in blood pressure that are typically pro-
duced by this agent.
Surgery is indicated for treatment of neonatal hyper-
tension in a limited set of circumstances [84]. In particu-
lar, hypertension caused by ureteral obstruction or aortic
coarctation [48] is best approached surgically. For in-
fants with renal arterial stenosis, it may be necessary to
manage the infant medically until it has grown suffi-
Table 3 Intravenous agents for acute hypertension and hypertensive emergencies/urgencies (ACE angiotensin converting enzyme, IV in-
travenous, BPD bronchopulmonary dysplasia)
Drug Class Dose Route Comments
Diazoxide Vasodilator 2–5 mg/kg per dose Rapid bolus injection Slow injection ineffective; 
(arteriolar) duration unpredictable;
use with caution – may cause
rapid hypotension
Enalaprilat ACE inhibitor 15±5 µg/kg per dose Injection over 5–10 min May cause prolonged hypotension
Repeat Q 8–24 h and acute renal insufficiency
Esmolol β blocker Drip: 100–300 µg/kg IV infusion Very short-acting – constant infusion 
per min necessary
Hydralazine Vasodilator Bolus: 0.15–0.6 mg/kg IV bolus or infusion Tachycardia frequent side-effect; must
(arteriolar) per dose administer Q 4 h when given IV bolus
Drip: 0.75–5.0 µg/kg 
per min
Labetalol α & β blocker 0.20–1.0 mg/kg per dose IV bolus or constant Heart failure, BPD relative 
0.25–3.0 mg/kg per h infusion contraindications
Nicardipine Ca2+ channel 1–3 µg/kg per min Constant infusion May cause reflex tachycardia
blocker
Sodium nitroprusside Vasodilator 0.5–10 µg/kg per min Constant infusion Thiocyanate toxicity can occur 
(arteriolar & with prolonged (>72 h) use or
venous) in renal failure
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ciently to undergo definitive repair of the vascular abnor-
malities [85]. Outcome of such surgical procedures can
become quite good if performed at centers with a large
experience [86]. Infants with hypertension secondary to
Wilms tumor or neuroblastoma will require surgical tu-
mor removal [57, 58, 84], possibly following chemother-
apy. A case has also been made by some authors for re-
moval of multicystic-dysplastic kidneys because of the
risk of development of hypertension [37–39], although
this is controversial. Infants with malignant hypertension
secondary to polycystic kidney disease may require bi-
lateral nephrectomy. Fortunately, such severely affected
infants are quite rare.
Outcome of neonatal hypertension
The long-term prognosis for infants with hypertension is
in most cases quite good, depending of course on the un-
derlying etiology of the infant’s hypertension. For in-
fants with hypertension related to an umbilical arterial
catheter, the hypertension will usually resolve over time
[87, 88]. These infants may require increases in their an-
tihypertensive medications in the first several months
following discharge from the nursery as they undergo
rapid growth. Following this, it is usually possible to
wean their antihypertensives by making no further dose
increases as the infant continues to grow. Home blood
pressure monitoring by the parents is a crucially impor-
tant component of this process. It is our standard of care
to arrange for home blood pressure equipment, either a
Doppler or oscillometric device, for all infants dis-
charged from the NICU on antihypertensive medications.
Some forms of neonatal hypertension may persist be-
yond infancy. In particular, PKD and other forms of re-
nal parenchymal disease may continue to cause hyper-
tension throughout childhood [35, 36, 89]. Infants with
renal venous thrombosis may also remain hypertensive
[30], and some of these children will ultimately benefit
from removal of the affected kidney [29, 30]. Persistent
or late hypertension may also be seen in children who
have undergone repair of renal arterial stenosis [86] or
thoracic aortic coarctation [48]. Reappearance of hyper-
tension in these situations should prompt a search for re-
stenosis by the appropriate imaging studies.
Conclusions
Blood pressure in neonates depends on a variety of fac-
tors, including gestational age, post-natal age and birth
weight. Hypertension can be seen in a variety of situa-
tions in the modern NICU, and is especially common in
infants who have undergone umbilical arterial catheter-
ization. A careful diagnostic evaluation should lead to de-
termination of the underlying cause of hypertension in
Table 4 Oral agents useful for hypertension in infants
Drug Class Dose Interval Comments
Captopril ACE Inhibitor <6 m: 0.01–0.5 mg/kg TID Drug of choice for most neonatal HTN
per dose monitor serum creatinine and K+
Max 6 mg/kg per day
Clonidine Central α agonist 0.05–0.1 mg per dose BID–TID Side effects include dry mouth & sedation;
rebound hypertension with abrupt 
discontinuation
Hydralazine Vasodilator (arteriolar) 0.25–1.0 mg/kg per dose TID–QID Suspension stable up to 1 week; 
Max 7.5 mg/kg per day tachycardia & fluid retention common 
side-effects; lupus-like syndrome may 
develop in slow acetylators
Isradipine Ca2+ channel blocker 0.05–0.15 mg/kg per dose QID Suspension may be compounded; useful 
Max 0.8 mg/kg per day for both acute & chronic HTN
Amlodipine Ca2+ channel blocker 0.1–0.3 mg/kg per dose BID Less likely to cause sudden hypotension 
Max 0.6 mg/kg per day than isradipine
Minoxidil Vasodilator (arteriolar) 0.1–0.2 mg/kg per dose BID–TID Most potent oral vasodilator; excellent 
for refractory HTN
Propranolol β – blocker 0.5–1.0 mg/kg per dose TID Maximal dose depends on heart rate; 
may go as high as 8–10 mg/kg per day 
if no bradycardia. Avoid in infants 
with BPD
Labetalol α and β blocker 1.0 mg/kg per dose BID–TID Monitor heart rate; avoid in infants 
Max. 10 mg/kg per day with BPD
Spironolactone Aldosterone antagonist 0.5–1.5 mg/kg per dose BID Potassium “sparing”; monitor electrolytes. 
Takes several days to see maximum 
effectiveness
Hydrochlorothiazide Thiazide diuretic 1–3 mg/kg per dose QID Monitor electrolytes
Chlorothiazide Thiazide diuretic 5–15 mg/kg per dose BID Monitor electrolytes
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most infants. Treatment decisions should be tailored to
the severity of the hypertension, and may include intrave-
nous and/or oral therapy. Most infants will resolve their
hypertension over time, although a small number may
have persistent blood pressure elevation throughout child-
hood.
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